Genmab — Januar 2019
-
OK teller. Har ikke lige fulgt med men du mener FDA forsinker godkendelsen p.t ? Ansøgningen da mig bekendt ikke sendt endnu ? Så jeg kan ikke lige se noget salgstab for vi forventer vel tidligst 1st line i Q3 og hvis det kommer tidligere er det sokkerne der ryger af
-
Johnson & Johnson Reports 2018 Fourth-Quarter Results:
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared to the...
(www.prnewswire.com)
-
The Company announced its 2019 full-year guidance for sales of $80.4 billion to $81.2 billion reflecting expected operational growth in the range of 0.0% to 1.0% and expected adjusted operational growth in the range of 2.0% to 3.0%. The Company also announced adjusted earnings guidance for full-year 2019 of $8.50 to $8.65 per share reflecting expected operational growth in the range of 5.7% to 7.6%.* Adjusted earnings guidance excludes the impact of after-tax intangible amortization expense and
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind